Drug intelligence / Profile preview

HEC116094

Development stage: Phase 1
Lead developer: Sunshine Lake Pharma
Modality: Small Molecules
Administration: Oral

Overview

HEC116094 is a small molecule investigational drug developed by Sunshine Lake Pharma. It has been evaluated in Phase 1 clinical trials for its safety, tolerability, pharmacokinetics (PK), food effect, and potential drug-drug interaction with oseltamivir in healthy adult subjects. The primary indication under investigation is influenza. Publicly available information on the compound's precise mechanism of action or molecular target is limited; it appears to be an experimental antiviral candidate or adjunct therapy for influenza management[2][3][4].

Targets

p3 (Amyloid-beta p3 fragment)

Beyond the preview

Go deeper on HEC116094.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HEC116094.

Explore the full profile